Assessment Status |
Awaiting response from Applicant |
HTA ID |
22024 |
Drug |
Enfortumab vedotin |
Brand |
Padcev® |
Indication |
As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor |
Rapid review commissioned |
22/04/2022 |
Rapid review completed |
18/05/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enfortumab vedotin (Padcev®) compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
27/05/2022 |
Pre-submission consultation with Applicant |
19/07/2022 |
Full submission received from Applicant |
23/11/2022 |
Preliminary review sent to Applicant |
16/03/2023 |